Skip to Content

Tenax Therapeutics, Inc. 

Securities Class Action

  • Date:
  • 12/28/26
  • Company Name:
  • Tenax Therapeutics, Inc.
  • Class Period:
  • FROM 11/13/23 TO 8/7/26
  • Status:
  • Filed
  • Filing Date:
  • 10/26/26

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Tenax Therapeutics, Inc. (“Tenax” or the “Company”) (NASDAQ:TENX) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Tenax securities between November 13, 2023 and August 7, 2026, both dates inclusive (the “Class Period”). Investors have until December 28, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) TNX-103 was less effective than Defendants had led investors to believe; (ii) accordingly, TNX-103's overall clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

The truth began to emerge on August 10, 2026, when Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. This press release stated that TNX-103 "did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score."

On this news, Tenax's stock price fell approximately $12.06 per share, or 89.77%, to close at approximately $1.38 per share on August 10, 2026.

If you purchased or otherwise acquired Tenax shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions

Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.

The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Tenax Therapeutics, Inc. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.